Extracellular chromosome 21-derived microRNAs in euploid & aneuploid pregnancies
- PMID: 24521639
- PMCID: PMC3978985
Extracellular chromosome 21-derived microRNAs in euploid & aneuploid pregnancies
Abstract
Background & objectives: Trisomy 21 is the most common chromosomal aneuploidy in live born infants. Recently, the over expression of chromosome 21-derived microRNAs (miR-99a, let-7c, miR-125b-2, miR-155 and miR-802) in human fetal hippocampus and heart samples from individuals with Down syndrome was observed. Therefore, concentrations and expression profile of extracellular chromosome 21-derived microRNAs were studied to verify their ability to distinguish noninvasively between pregnancies bearing euploid fetuses and those affected with Down syndrome.
Methods: RNA enriched for small RNAs was isolated from plasma samples of 12 pregnant women with high risk of bearing Down syndrome foetuses (median gestation 18.5 wk), 12 women with normal course of gestation and 10 non-pregnant women. MicroRNA transcribed into cDNA using specific stem-loop primer was detected using real-time PCR assay. Simulation experiments using RNA pools of healthy non-pregnant individuals and aneuploid amniotic fluid samples in descending dilution ratio ranging from 1:1 to 1000:1 were used to test the detection limit of the technique for overexpressed chromosome 21-derived microRNAs specific for Down syndrome. The expression profile of the gene encoding microRNA was studied through the relative gene expression using the comparative Ct (threshold cycle) method. Concentrations of individual microRNAs were subtracted from the calibration curves in the course of analyses and expressed as pg of total RNA per milliliter of plasma.
Results: Four of the five extracellular chromosome 21-derived microRNAs (miR-99a, let-7c, miR-125b-2 and miR-155) were reliably detected in plasma samples. Simulation experiments revealed the detection limit of aneuploidy at a ratio 100:1 for let-7c, miR-125b-2 and miR-155, and a ratio of 1000:1 for miR-99a. Overexpression of extracellular miR-99a, miR-125b-2 and miR-155 was observed in pregnant women compared to non-pregnant women. Similarly, increased concentrations of extracellular miR-99a and miR-125b-2 were detected in pregnant women than in non-pregnant women. The concentrations and relative gene expression of extracellular chromosome 21-derived microRNAs did not differ between the cohorts of pregnancies bearing euploid foetuses and those affected with Down syndrome.
Interpretation & conclusions: Analysis of extracellular chromosome 21-derived microRNAs has no benefit for screening programmes and non-invasive diagnosis of Down syndrome.
Figures


Similar articles
-
[Extracellular chromosome 21--derived microRNAs in maternal circulation: evaluation of their diagnostic potential for screening of Down syndrome].Ceska Gynekol. 2012 Oct;77(5):395-402. Ceska Gynekol. 2012. PMID: 23116342 Czech.
-
Mature miR-99a Upregulation in the Amniotic Fluid Samples from Female Fetus Down Syndrome Pregnancies: A Pilot Study.Medicina (Kaunas). 2019 Nov 7;55(11):728. doi: 10.3390/medicina55110728. Medicina (Kaunas). 2019. PMID: 31703316 Free PMC article.
-
Expression patterns of the chromosome 21 MicroRNA cluster (miR-99a, miR-125b and let-7c) in chorioamniotic membranes.Placenta. 2017 Jan;49:1-9. doi: 10.1016/j.placenta.2016.11.002. Epub 2016 Nov 9. Placenta. 2017. PMID: 28012448 Free PMC article.
-
Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies.J Obstet Gynaecol Can. 2011 Sep;33(9):955-960. doi: 10.1016/S1701-2163(16)35022-8. J Obstet Gynaecol Can. 2011. PMID: 21923994 Review.
-
Mouse models of aneuploidy to understand chromosome disorders.Mamm Genome. 2022 Mar;33(1):157-168. doi: 10.1007/s00335-021-09930-z. Epub 2021 Nov 1. Mamm Genome. 2022. PMID: 34719726 Free PMC article. Review.
Cited by
-
Differentially expressed microRNAs in maternal plasma for the noninvasive prenatal diagnosis of Down syndrome (trisomy 21).Biomed Res Int. 2014;2014:402475. doi: 10.1155/2014/402475. Epub 2014 Nov 12. Biomed Res Int. 2014. PMID: 25478570 Free PMC article.
-
MicroRNA Expression Profile in the Prenatal Amniotic Fluid Samples of Pregnant Women with Down Syndrome.Balkan Med J. 2018 Mar 15;35(2):163-166. doi: 10.4274/balkanmedj.2017.0511. Epub 2017 Dec 8. Balkan Med J. 2018. PMID: 29219113 Free PMC article.
-
Prenatal circulating microRNA signatures of foetal Down syndrome.Sci Rep. 2019 Feb 20;9(1):2394. doi: 10.1038/s41598-018-35876-5. Sci Rep. 2019. PMID: 30787377 Free PMC article.
-
Genome-wide miRNA profiling in plasma of pregnant women with down syndrome fetuses.Mol Biol Rep. 2020 Jun;47(6):4531-4540. doi: 10.1007/s11033-020-05545-w. Epub 2020 May 30. Mol Biol Rep. 2020. PMID: 32472298 Free PMC article.
-
Liquid Biopsy in Adverse Neurodevelopment of Children: Problems and Prospects.Methods Mol Biol. 2023;2695:337-349. doi: 10.1007/978-1-0716-3346-5_23. Methods Mol Biol. 2023. PMID: 37450130 Review.
References
-
- Centers for Disease Control and Prevention. Improved national prevalence estimates for 18 selected major birth defects-United States, 1999-2001. Morb Mortal Wkly Rep. 2006;54:1301–5. - PubMed
-
- Savva GM, Morris JK, Mutton DE, Alberman E. Maternal age-specific fetal loos rates in Down syndrome pregnancies. Prenatal Diagn. 2006;26:499–504. - PubMed
-
- Nicolaides KH. Screening for chromosomal defects. Ultrasound Obstet Gynecol. 2003;21:313–21. - PubMed
-
- Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med. 2005;353:2001–11. - PubMed
-
- Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005;25:221–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical